Clinical Trials Directory

Trials / Suspended

SuspendedNCT05715619

Safety and Efficacy of Oral Administration of the Phage Cocktail, VRELysin™, In Healthy and VRE-Colonized Subjects

A Phase 1/2a Double-Blind, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Oral Administration of the Phage Cocktail, VRELysin™, In Healthy And VRE-Colonized Subjects

Status
Suspended
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
80 (estimated)
Sponsor
Intralytix, Inc. · Industry
Sex
All
Age
18 Years – 50 Years
Healthy volunteers
Accepted

Summary

The study is a first-in-human Phase 1/2a randomized, double-blind, placebo-controlled trial to assess the clinical safety and efficacy of VRELysin in healthy and VRE-colonized adults.

Detailed description

The purpose of this study is to determine if VRELysin is safe and effective in adults in a continuous Phase 1/2a trial. Phase 1 will asses the safety of VRELysin in healthy adults, while Phase 2a will evaluate the safety and efficacy of VRELysin in adults colonized with VRE in the gastrointestinal tract. VRELysin is a collection of bacteriophages. Bacteriophages (or phages) are viruses that infect only bacteria. The phages in VRELysin infect a specific type of bacteria called Enterococcus, which can cause gastrointestinal infections. VRELysin is intended to significantly reduce or eliminate vancomycin-resistant Enterococcus (VRE) levels in the human gastrointestinal tract, which in turn, may prevent subsequent infection as well as nosocomial spread.

Conditions

Interventions

TypeNameDescription
BIOLOGICALVRELysin™A cocktail of lytic Enterococcus-specific bacteriophages orally administered with sodium bicarbonate solution
OTHERPlaceboPlacebo orally administered with sodium bicarbonate solution

Timeline

Start date
2023-10-25
Primary completion
2026-10-31
Completion
2026-10-31
First posted
2023-02-08
Last updated
2026-04-14

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT05715619. Inclusion in this directory is not an endorsement.